Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders

NCT00157079 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immunodeficiency Diseases (PID)
Immune Thrombocytopenic Purpura (ITP)
Kawasaki Syndrome

Interventions

BIOLOGICAL: Immune Globulin Intravenous (Human), 10%

Sponsor

Baxalta now part of Shire